This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HCV	Inosine triphosphatase (ITPA)	<p>Genomewide studies suggest that genetic variation in the <i>ITPA</i> gene could help predict susceptibility to treatment-associated anemia in HCV patients receiving standard therapy. Genomewide studies of HCV patients receiving pegylated interferon-α (IFNA; IFN-α) and ribavirin therapy showed that SNP rs6051702 was significantly associated with protection from treatment-induced anemia ($p=1.1\times 10^{-45}$). The SNP also was associated with two known <i>ITPA</i> variants that lead to benign ITPA deficiency. Next steps could include assessing the role of <i>ITPA</i> variants in anemia induced by other therapies.</p> <p>SciBX 3(9); doi:10.1038/scibx.2010.281 Published online March 4, 2010</p>	Patented by Merck & Co. Inc.; licensing status unavailable	<p>Fellay, J. <i>et al. Nature</i>; published online Feb. 21, 2010; doi:10.1038/nature08825</p> <p>Contact: David Goldstein, Duke University, Durham, N.C. e-mail: d.goldstein@duke.edu</p>